Nicole White
Corporate Officer/Principal chez ASSEMBLY BIOSCIENCES, INC.
Fortune : 171 716 $ au 30/04/2024
Postes actifs de Nicole White
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| ASSEMBLY BIOSCIENCES, INC. | Corporate Officer/Principal | 17/11/2020 | - |
Historique de carrière de Nicole White
Anciens postes connus de Nicole White
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| GOSSAMER BIO, INC. | Corporate Officer/Principal | 01/05/2018 | 01/11/2020 |
Abide Therapeutics, Inc.
 Abide Therapeutics, Inc. Pharmaceuticals: OtherHealth Technology Abide Therapeutics, Inc. develops medicines that target serine hydrolases. Its approach is to selectively block serine hydrolases, potentially expanding this class of commercially validated enzymes as targets in a range of indications. The firm has a technology platform that exploits a chemoproteomics approach to selectively target serine hydrolases and rapidly identify target lead pairs. The company was founded by Alan B. Ezekowitz, Dale Boger, John Kennedy Clarke, Benjamin F. Cravatt, Todd Jones, Keith F. Lenden, and Paul R. Schimmel in 2011 and is headquartered in San Diego, CA. | Corporate Officer/Principal | 01/10/2015 | 01/04/2018 |
| GILEAD SCIENCES, INC. | Corporate Officer/Principal | 01/03/2009 | 01/10/2015 |
Formation de Nicole White
| University of California, Irvine | Doctorate Degree |
| University of California San Diego | Undergraduate Degree |
Statistiques
Internationale
| Etats-Unis | 7 |
Opérationnelle
| Corporate Officer/Principal | 4 |
| Doctorate Degree | 1 |
| Undergraduate Degree | 1 |
Sectorielle
| Health Technology | 5 |
| Consumer Services | 3 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| ASSEMBLY BIOSCIENCES, INC. | Health Technology |
| GOSSAMER BIO, INC. | Health Technology |
| GILEAD SCIENCES, INC. | Health Technology |
| Entreprise privées | 1 |
|---|---|
Abide Therapeutics, Inc.
Abide Therapeutics, Inc. Pharmaceuticals: OtherHealth Technology Abide Therapeutics, Inc. develops medicines that target serine hydrolases. Its approach is to selectively block serine hydrolases, potentially expanding this class of commercially validated enzymes as targets in a range of indications. The firm has a technology platform that exploits a chemoproteomics approach to selectively target serine hydrolases and rapidly identify target lead pairs. The company was founded by Alan B. Ezekowitz, Dale Boger, John Kennedy Clarke, Benjamin F. Cravatt, Todd Jones, Keith F. Lenden, and Paul R. Schimmel in 2011 and is headquartered in San Diego, CA. | Health Technology |
- Bourse
- Insiders
- Nicole White
- Expérience